| Balance Sheets | 2026-02-28 | 2025-08-31 | 2025-05-31 | |
|---|---|---|---|---|
| Cash & cash equivalents | 0 | 0 | 0 | |
| Accounts receivable | 0 | 0 | 0 | |
| Interest receivable | 0 | 0 | 0 | |
| Total current assets | 0 | 0 | 0 | |
| Intangibles (net) | 0 | 0 | 0 | |
| Equipment (net) | 670 | 0 | 0 | |
| Other assets (exousia ai) | 22,050,000 | NaN | NaN | |
| Total non-current assets | 22,050,670 | 0 | 0 | |
| Total assets | 22,050,670 | 0 | 0 | |
| Accrued expenses | NaN | NaN | 0 | |
| Due to related party | 8,831 | NaN | NaN | |
| Advances from related parties | 38,850 | NaN | 0 | |
| Due to related party | NaN | 7,064 | NaN | |
| Accounts payable | 212,302 | NaN | NaN | |
| Advances from related parties | NaN | 28,250 | NaN | |
| Other current liabilities | 1,040 | NaN | NaN | |
| Total current liabilities | 261,023 | 35,314 | 0 | |
| Loans from related parties | 0 | 0 | 0 | |
| Note payable related party | 0 | 0 | 0 | |
| Note payable others | 0 | 0 | 0 | |
| Accrued interest | 0 | 0 | 0 | |
| Total non-current liabilities | 0 | 0 | 0 | |
| Total liabilities | 261,023 | 35,314 | 0 | |
| Common stock, 0.0001par value, 100,000,000 shares authorized 70,000,000 & 7,777,000 shares issued and outstanding as of february 2026, and may 31, 2025, respectively | 7,350 | 778 | 778 | |
| Preferred series x | 0 | NaN | NaN | |
| Additional paid-in-capital | 22,070,920 | 27,492 | 30,992 | |
| Accumulated deficit | -288,623 | -63,584 | -31,770 | |
| Total stockholders equity (deficit) | 21,789,647 | -35,314 | 0 | |
| Total liabilities and stockholders equity (deficit) | 22,050,670 | 0 | 0 | |
Exousia Bio, Inc. (LMMY)
Exousia Bio, Inc. (LMMY)